The Steady-State Serum Concentration of Genistein Aglycone Is Affected by Formulation: A Bioequivalence Study of Bone Products
Figure 3
The pharmacokinetic profile for the first 24 hours after the last dose of each study product obtained after 8 days 54 mg per day intake of the medical food indicated for osteopenia/osteoporosis , the Squadrito study formulation and the OTC bone supplement . * for the medical food versus the OTC bone supplement, + for the Squadrito study formulation versus the OTC bone supplement.
